Compare ARK Genomic Revolution ETF (ARKG) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Avantis US Small Cap Value ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.6, while Avantis US Small Cap Value ETF trades at $124.4. The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | AVUV | |
|---|---|---|
Sector | Sector/Thematic | Sector/Thematic |
52-Week High | $43.57 | $124.94 |
52-Week Low | $23.09 | $90.37 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
AVUV trades at $123.95, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on U.S. small-cap value stocks, showing strong performance in 2026 amid a rotation from growth. Recent news highlights its role in diversifying tech-heavy portfolios and benefiting from potential rate cuts.
Outlook remains positive due to small-cap value momentum and macroeconomic tailwinds, but risks include exposure to regional banks and sensitivity to interest rates. The ETF offers diversification but faces volatility from unproven companies and economic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
